Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.52 |
| ▸ | RET | P07949 | 7/20 | 0.46 |
| ▸ | KDR | P35968 | 7/20 | 0.46 |
| ▸ | KIF5B | P33176 | 4/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | STK10 | O94804 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.45 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10945990 | 0.94 | EGFR (0.52) | EGFRRETKDRKIF5BENPP1 | |
| Quazodine SCHEMBL636671 | 0.87 | ENPP1 (0.58) | EGFRRETKDRENPP1GAK | |
| SCHEMBL7802744 | 0.83 | EGFR (0.53) | EGFRRETKDRKIF5BGAK | |
| SCHEMBL16281258 | 0.83 | EGFR (0.38) | EGFRRETKDRKIF5BENPP1 | |
| SCHEMBL24392236 | 0.81 | ENPP1 (0.68) | EGFRRETKDRENPP1GAK | |
| SCHEMBL11315816 | 0.79 | EGFR (0.52) | EGFRRETKDRKIF5BGAK | |
| SCHEMBL10296332 | 0.79 | KDR (0.52) | EGFRRETKDRKIF5BENPP1 | |
| SCHEMBL20813470 | 0.79 | EGFR (0.52) | EGFRRETKDRKIF5BGAK | |
| SCHEMBL3529124 | 0.78 | KDR (0.51) | EGFRRETKDRKIF5BGAK | |
| SCHEMBL296984 | 0.78 | ENPP1 (0.63) | EGFRRETKDRKIF5BENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-08-25 | — | — | US | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-4495352-A | HYPOTENSIVE AGENTS; VASODILATION; ADRENERGIC BLOCKING ACTION | MEAD JOHNSON & COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| US-4343940-A | 6- AND/OR 7-SUBSTITUTED WITH OXIRANYLMETHOXY | MEAD JOHNSON & COMPANY (US) | 1982-08-10 | — | — | US | disclosed |
| US-4314943-A | ANTIHYPERTENSIVE AGENTS; VASODILATORS | MEAD JOHNSON & COMPANY (US) | 1982-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | EGFR 59/4885RET 8/4885KDR 70/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | EGFR 46/4885RET 9/4885KDR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.